Introducing the HemaSphere Controversies Series
Open Access
- 27 September 2019
- journal article
- editorial
- Published by Wiley in HemaSphere
- Vol. 3 (5), e296
- https://doi.org/10.1097/hs9.0000000000000296
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaThe New England Journal of Medicine, 2019
- Controversies in the Treatment of Classical Hodgkin LymphomaHemaSphere, 2018
- Advances in B‐cell Precursor Acute Lymphoblastic Leukemia GenomicsHemaSphere, 2018
- Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupThe Lancet Oncology, 2017
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Monitoring disease burden in chronic myeloid leukemia: Past, present, and futureAmerican Journal of Hematology, 2016
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's LymphomaThe New England Journal of Medicine, 2008